Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Caitlin E. Cox

September 03, 2020

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Industry News

Angel Medical Systems Inc. Assembles World-Class Medical Advisory Board

September 20, 2019

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

Podcast TCTMD Talking Points

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

September 05, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Podcast TCTMD Talking Points

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

May 23, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

Podcast TCTMD Talking Points

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

April 18, 2018

Podcast TCTMD Talking Points

Robotic PCI in Practice and Training

April 04, 2018

Podcast TCTMD Talking Points

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

March 21, 2018

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Todd Neale

May 05, 2017

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

Advertisement

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Angel Medical Systems Inc. Assembles World-Class Medical Advisory Board

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

Robotic PCI in Practice and Training

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

Live From Denver: TCT 2017, Day Three

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content